Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Stem Cell Transplantation"" wg kryterium: Temat


Starter badań:

Tytuł :
Outcomes of unrelated donor stem cell transplantation with or without anti-thymocyte globulin used as graft-versus-host disease prophylaxis in patients with acute leukaemia and myelodysplastic syndrome.
Autorzy :
Gener G; Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia, Josep Carreras, Barcelona, España. Electronic address: .
Batlle M; Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia, Josep Carreras, Barcelona, España.
Morgades M; Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia, Josep Carreras, Barcelona, España.
Jiménez MJ; Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia, Josep Carreras, Barcelona, España.
Ferrà C; Universitat de Vic, Universitat Central de Catalunya, Vic, España.
Ribera JM; Universitat Autònoma de Barcelona, Badalona, España.
Pokaż więcej
Transliterated Title :
Resultados del trasplante de progenitores hematopoyéticos de donante no emparentado con o sin globulina antitimocítica como profilaxis de la enfermedad del injerto contra receptor en pacientes con leucemia aguda y síndrome mielodisplásico.
Źródło :
Medicina clinica [Med Clin (Barc)] 2021 Oct 22; Vol. 157 (8), pp. 380-384. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Case Reports
MeSH Terms :
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute*/complications
Leukemia, Myeloid, Acute*/therapy
Myelodysplastic Syndromes*/complications
Myelodysplastic Syndromes*/therapy
Antilymphocyte Serum/therapeutic use ; Humans ; Neoplasm Recurrence, Local ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation Conditioning ; Transplantation, Homologous ; Unrelated Donors
Raport
Tytuł :
Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation.
Autorzy :
Rademacher JG; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. .
Wulf G; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
Koziolek MJ; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Zeisberg M; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Wallbach M; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Pokaż więcej
Źródło :
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs [J Artif Organs] 2021 Sep; Vol. 24 (3), pp. 402-406. Date of Electronic Publication: 2021 Jan 18.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lymphohistiocytosis, Hemophagocytic*/diagnosis
Lymphohistiocytosis, Hemophagocytic*/therapy
Lymphoma*
Adsorption ; Cytokines ; Humans ; Stem Cell Transplantation ; Transplantation Conditioning
Czasopismo naukowe
Tytuł :
T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection.
Autorzy :
Kuzich JA; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. .
Kankanige Y; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; University of Melbourne, Parkville, VIC, Australia.
Guinto J; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Ryland G; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; University of Melbourne, Parkville, VIC, Australia.
McBean M; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Wong E; University of Melbourne, Parkville, VIC, Australia.; Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia.; ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australia.; Department of Clinical Haematology, Austin Hospital, Heidelberg, VIC, Australia.
Koldej R; University of Melbourne, Parkville, VIC, Australia.; ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australia.
Collins J; Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia.
Westerman D; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; University of Melbourne, Parkville, VIC, Australia.; Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia.
Ritchie D; University of Melbourne, Parkville, VIC, Australia.; Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia.; ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australia.
Blombery P; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; University of Melbourne, Parkville, VIC, Australia.; Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Oct; Vol. 56 (10), pp. 2582-2590. Date of Electronic Publication: 2021 May 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytomegalovirus Infections*
Hematopoietic Stem Cell Transplantation*/adverse effects
Cytomegalovirus ; Humans ; Receptors, Antigen, T-Cell/genetics ; Stem Cell Transplantation/adverse effects ; Transplantation, Homologous ; Virus Activation
Czasopismo naukowe
Tytuł :
Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
Autorzy :
Koo RM; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Ritchie D; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Oct; Vol. 62 (10), pp. 2303-2305.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease*/therapy
Humans ; Neoplasm Recurrence, Local ; Stem Cell Transplantation ; Transplantation Conditioning ; Transplantation, Autologous ; Transplantation, Homologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.
Autorzy :
Vijenthira A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Kuruvilla J; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Prica A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Oct; Vol. 56 (10), pp. 2400-2409. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lymphoma, Follicular*/therapy
Canada ; Cost-Benefit Analysis ; Humans ; Immunotherapy ; Neoplasm Recurrence, Local ; Phosphatidylinositol 3-Kinases ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.
Autorzy :
Jamy O; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Innis-Shelton R; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Bal S; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Paluri R; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Salzman D; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Di Stasi A; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Costa L; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Meredith R; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Lamb L; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Minagawa K; Division of Hematology and Oncology, Department of Medicine, Pennsylvania State University, University Park, Pennsylvania, USA.
Mineishi S; Division of Hematology and Oncology, Department of Medicine, Pennsylvania State University, University Park, Pennsylvania, USA.
Saad A; Division of Hematology and Oncology, Department of Medicine, Ohio State University, Columbus, Ohio, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Oct 01; Vol. 96 (10), pp. E396-E398. Date of Electronic Publication: 2021 Jul 31.
Typ publikacji :
Clinical Trial, Phase II; Letter
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*/adverse effects
Cyclophosphamide/*therapeutic use
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Cyclophosphamide/administration & dosage ; Female ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Immunosuppressive Agents/administration & dosage ; Incidence ; Male ; Middle Aged ; Myeloablative Agonists/therapeutic use ; Unrelated Donors
Raport
Tytuł :
Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.
Autorzy :
Luft T; Department Medicine V, University of Heidelberg, Heidelberg, Germany. .
Dreger P; Department Medicine V, University of Heidelberg, Heidelberg, Germany. .
Radujkovic A; Department Medicine V, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Oct; Vol. 56 (10), pp. 2326-2335. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Endothelial Cells ; Humans ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation Conditioning ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.
Autorzy :
Kanter J; Department of Hematology-Oncology, University of Alabama Birmingham, Birmingham, AL.
Liem RI; Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
Bernaudin F; French Referral Center for Sickle Cell Disease, Centre Hospitalier Intercommunal Créteil, Université Paris XII, Paris, France.; Société Française de Greffe de Moelle et de Thérapie Cellulaire, Lille, France.
Bolaños-Meade J; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Fitzhugh CD; Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
Hankins JS; Department of Hematology, St Jude Children's Research Hospital, Memphis, TN.
Murad MH; Division of Preventive Medicine, Mayo Clinic, Rochester, MN.
Panepinto JA; Medical College of Wisconsin/Children's Wisconsin, Pediatric Hematology, Milwaukee, WI.
Rondelli D; Division of Hematology-Oncology, University of Illinois at Chicago, Chicago, IL.
Shenoy S; St Louis Children's Hospital, Washington University School of Medicine, St Louis, MO.
Wagner J; Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Walters MC; Benioff Children's Hospital, University of California San Francisco, Oakland, CA.
Woolford T; Sickle Cell Reproductive Health Education Directive, Owings Mills, MD.
Meerpohl JJ; Institute for Evidence in Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; and.; Cochrane Germany Foundation, Cochrane Germany, Freiburg, Germany.
Tisdale J; Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 Sep 28; Vol. 5 (18), pp. 3668-3689.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Anemia, Sickle Cell*/therapy
Hematology*
Hematopoietic Stem Cell Transplantation*
Humans ; Quality of Life ; Stem Cell Transplantation ; United States
Czasopismo naukowe
Tytuł :
Large-vessel vasculitis in graft-versus-host disease: a case report.
Autorzy :
Al-Heilfi A; Royal Hobart Hospital, Hobart, TAS, Australia. .
Nataraja C; Royal Hobart Hospital, Hobart, TAS, Australia.
Cooley H; Royal Hobart Hospital, Hobart, TAS, Australia.
Batt T; Royal Hobart Hospital, Hobart, TAS, Australia.
Pokaż więcej
Źródło :
Journal of medical case reports [J Med Case Rep] 2021 Sep 28; Vol. 15 (1), pp. 478. Date of Electronic Publication: 2021 Sep 28.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Graft vs Host Disease*/complications
Graft vs Host Disease*/diagnosis
Hematopoietic Stem Cell Transplantation*/adverse effects
Vasculitis*/etiology
Humans ; Male ; Middle Aged ; Stem Cell Transplantation ; Transplantation, Homologous/adverse effects
Czasopismo naukowe
Tytuł :
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Autorzy :
Rubinstein JD; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Oncology and.
Zhu X; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Leemhuis T; Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH.
Pham G; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Ray L; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Emberesh S; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Jodele S; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Thomas S; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Cancelas JA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH.
Bollard CM; Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, DC.
Hanley PJ; Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, DC.
Keller MD; Department of Pediatrics, Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, DC.
Grimley O; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Clark D; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Clark T; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Lindestam Arlehamn CS; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA; and.
Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA; and.; Department of Medicine, University of California San Diego, La Jolla, CA.
Davies SM; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Nelson AS; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Grimley MS; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Lutzko C; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.; Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 Sep 14; Vol. 5 (17), pp. 3309-3321.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenoviridae Infections*/therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Child ; Humans ; Interferon-gamma ; Stem Cell Transplantation/adverse effects ; T-Lymphocytes
Czasopismo naukowe
Tytuł :
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
Autorzy :
Eyre TA; Department of Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. .
Caillard S; Nephrology Transplantation Department, Strasbourg University Hospitals, Strasbourg, France.
Finel H; Lymphoma Working Party EBMT, Paris, France.
Boumendil A; Lymphoma Working Party EBMT, Paris, France.
Kothari J; Department of Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Zimmermann H; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.
Trappe RU; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.; Department of Internal Medicine II: Hematology and Oncology, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany.; Department of Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
De Wilde V; Erasmus Hospital, Route de Lennik 808, 1070, Bruxelles, Belgium.
Tholouli E; Manchester Royal Infirmary, Oxford Road, Manchester, UK.
Kanfer E; Department of Haematology, Hammersmith Hospital, London, UK.
Broom A; Department of Haematology, Western General Hospital, Edinburgh, UK.
Damaj G; Department of Haematology, Hospital Center University of Caen, Caen, Normandy, France.
Bargetzi M; Department of Haematology, Kantonsspital, Aarau, Switzerland.
Kozák T; Department of Haematology, Charles University Hospital, Prague, Czech Republic.
Hilgendorf I; Department of Haematology, Jena University Hospital, Jena, Germany.
Crawley C; Department of Haematology, Addenbrookes Hospital, Cambridge, UK.
Kerre T; Department of Haematology, Ghent University Hospital, Ghent, Belgium.
Trněný M; Department of Haematology, Charles University Hospital, Prague, Czech Republic.
Bachy E; Department of Haematology, Hospices Civils, Lyon, France.
Robinson S; Lymphoma Working Party EBMT, Paris, France.; BMT Unit, University Hospital Bristol NHS Foundation Trust, Bristol, UK.
Montoto S; Lymphoma Working Party EBMT, Paris, France.; Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Sep; Vol. 56 (9), pp. 2118-2124. Date of Electronic Publication: 2021 Apr 16.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma, Large B-Cell, Diffuse*
Lymphoproliferative Disorders*/etiology
Lymphoproliferative Disorders*/therapy
Organ Transplantation*/adverse effects
Humans ; Neoplasm Recurrence, Local ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey).
Autorzy :
Russo D; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. .
Polverelli N; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. .
Malagola M; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
Farina M; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
Leoni A; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
Bernardi S; Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.; Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili di Brescia, Brescia, Italy.
Mammoliti S; GITMO Trials Office, Genova, Italy.
Sacchi N; Italian Bone Marrow Donor Registry, Galliera Hospital, Genova, Italy.
Martino M; Stem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and radiotherapy, Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli', Reggio Calabria, Italy.
Ciceri F; San Raffaele Scientific Institute, Milan, Italy.
Pokaż więcej
Corporate Authors :
GITMO Centers
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Sep; Vol. 56 (9), pp. 2272-2275. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*
Humans ; Italy/epidemiology ; Pandemics ; RNA, Viral ; SARS-CoV-2 ; Stem Cell Transplantation ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.
Autorzy :
Derenzini E; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy. .; Department of Health Sciences, University of Milan, Milan, Italy. .
Tabanelli V; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Sammassimo S; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Mazzara S; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Motta G; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Melle F; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Vanazzi A; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Calleri A; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Fiori S; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Finazzi MC; Hematology and Bone marrow Transplant Unit, ASST-Papa Giovanni XXIII, Bergamo, Italy.
Barbanti MC; Hematology and Bone marrow Transplant Unit, ASST-Papa Giovanni XXIII, Bergamo, Italy.
Ramadan S; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Gandini S; Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Pastano R; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Rambaldi A; Hematology and Bone marrow Transplant Unit, ASST-Papa Giovanni XXIII, Bergamo, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Pileri S; Haemolymphopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Tarella C; Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy. .; Department of Health Sciences, University of Milan, Milan, Italy. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Sep; Vol. 56 (9), pp. 2280-2283. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lymphoma*/therapy
Humans ; Neoplasm Recurrence, Local ; Stem Cell Transplantation
Raport
Tytuł :
Localized eruptive porokeratosis in pediatric patients following treatment of acute leukemia.
Autorzy :
Kang BY; Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA.
Jacobsen J; Department of Pathology, Phoenix Children's Hospital, Phoenix, AZ, USA.
Price HN; Department of Dermatology, Phoenix Children's Hospital, Phoenix, AZ, USA.
Andrews ID; Department of Dermatology, Phoenix Children's Hospital, Phoenix, AZ, USA.
Pokaż więcej
Źródło :
Pediatric dermatology [Pediatr Dermatol] 2021 Sep; Vol. 38 (5), pp. 1226-1232. Date of Electronic Publication: 2021 Aug 21.
Typ publikacji :
Case Reports
MeSH Terms :
Exanthema*
Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute*/therapy
Porokeratosis*/diagnosis
Porokeratosis*/etiology
Child ; Humans ; Stem Cell Transplantation
Raport
Tytuł :
[Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Autorzy :
Ning X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Wei X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Guo X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Wei Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Huang F; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Fan Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xu N; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Sun J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Feng R; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Wei Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Pokaż więcej
Źródło :
Nan fang yi ke da xue xue bao = Journal of Southern Medical University [Nan Fang Yi Ke Da Xue Xue Bao] 2021 Aug 31; Vol. 41 (9), pp. 1420-1425.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/drug therapy
Humans ; Lenalidomide/therapeutic use ; Neoplasm Recurrence, Local ; Proteasome Inhibitors/therapeutic use ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms.
Autorzy :
Jung EH; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Shin DY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Hong J; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Kim I; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Yoon SS; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Koh Y; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Byun JM; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea; .; Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2021 Jul-Aug; Vol. 35 (4), pp. 2379-2390.
Typ publikacji :
Journal Article
MeSH Terms :
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Neoplasms*
Humans ; Killer Cells, Natural ; Longitudinal Studies ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation Conditioning
Czasopismo naukowe
Tytuł :
Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.
Autorzy :
Mirgh S; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Gokarn A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Punatar S; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Chichra A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Singh A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Rajendra A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Babu Goli V; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Trivedi B; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Anaesthesiology, Pain and Critical Care Medicine, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Joshi A; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Patkar N; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Hemato-Pathology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Tembhare P; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Hemato-Pathology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Subramanian PG; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Hemato-Pathology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Shetty N; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Radiodiagnosis, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Chavan P; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Laboratory Medicine, ACTREC - Tata Memorial Centre, ACTREC, Navi Mumbai, Maharashtra, India.; Department of Microbiology, ACTREC - Tata Memorial Centre, ACTREC, Navi Mumbai, Maharashtra, India.
Bhat V; Homi Bhabha National Institute, Mumbai, Maharashtra, India.; Department of Microbiology, ACTREC - Tata Memorial Centre, ACTREC, Navi Mumbai, Maharashtra, India.
Gupta S; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Khattry N; Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, Maharashtra, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Pokaż więcej
Źródło :
Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2021 Aug; Vol. 23 (4), pp. e13576. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Case Reports
MeSH Terms :
COVID-19*/drug therapy
Graft vs Host Disease*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Antibodies, Monoclonal, Humanized ; Antiviral Agents/therapeutic use ; Humans ; Male ; Middle Aged ; SARS-CoV-2 ; Stem Cell Transplantation/adverse effects
SCR Protocol :
COVID-19 drug treatment
Raport
Tytuł :
Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
Autorzy :
Wenge DV; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Wethmar K; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Mikesch JH; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Reicherts C; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Schliemann C; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Mesters R; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Kessler T; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Khandanpour C; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Kerkhoff A; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Schmitz N; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Berdel WE; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Lenz G; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Stelljes M; Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Aug; Vol. 62 (8), pp. 1930-1939. Date of Electronic Publication: 2021 Mar 29.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hodgkin Disease*/therapy
Disease-Free Survival ; Humans ; Neoplasm Recurrence, Local ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation Conditioning ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
FLT3-ITDos and FLT3-ITDon'ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation.
Autorzy :
Ragon BK; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Aug; Vol. 56 (8), pp. 1774-1776. Date of Electronic Publication: 2021 Apr 28.
Typ publikacji :
Editorial
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/therapy
Humans ; Mutation ; Stem Cell Transplantation ; fms-Like Tyrosine Kinase 3/genetics
Opinia redakcyjna
Tytuł :
Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue.
Autorzy :
Haghiri S; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France.
Fayech C; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France.
Mansouri I; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Dufour C; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France.
Pasqualini C; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France.
Bolle S; Département de Radiothérapie Oncologique, Gustave Roussy, Villejuif, France.
Rivollet S; Unité de Psycho-Oncologie, Gustave Roussy, Villejuif, France.
Dumas A; Université de Paris, Inserm, ECEVE UMR 1123, Paris, France.
Boumaraf A; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Belhout A; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Journy N; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Souchard V; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Vu-Bezin G; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Veres C; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.; Département de Radiothérapie Oncologique, Gustave Roussy, Villejuif, France.
Haddy N; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
De Vathaire F; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France.
Valteau-Couanet D; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France.
Fresneau B; Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, Villejuif, France. .; Université Paris-Saclay, Inserm, Epidémiologie des radiations, CESP, Villejuif, France. .
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2021 Aug; Vol. 56 (8), pp. 1984-1997. Date of Electronic Publication: 2021 Apr 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Neuroblastoma*/therapy
Antineoplastic Combined Chemotherapy Protocols ; Female ; Follow-Up Studies ; Humans ; Male ; Stem Cell Transplantation ; Survivors ; Transplantation, Autologous
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies